Item 5.07 Submission
of Matters to a Vote of Security Holders.
Adverum Biotechnologies, Inc. held its 2021 Annual Meeting of Stockholders on May 12, 2021. The following is a brief description of each Proposal voted upon
at the Annual Meeting:
Proposal No. 1.
|
Election of Directors: This was a contested election to
elect three directors to serve until the 2024 Annual Meeting of Stockholders. Adverum had nominated three directors and The Sonic Fund II, L.P. (“Sonic”) had nominated three directors.
|
Proposal No. 2.
|
Ratification of Selection of Independent Registered Public Accounting Firm.
Adverum’s stockholders were asked to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31, 2021.
|
Proposal No. 3.
|
Advisory Approval of Executive Compensation. Adverum’s stockholders were
asked to approve, on an advisory basis, of the compensation of Adverum’s named executive officers, as disclosed in the proxy statement.
|
On May 13, 2021, First Coast Results, Inc. (“First Coast”), the independent
inspector of election for the Annual Meeting, delivered its final report of the inspector of election as to the voting results for each of these matters.
As of the close of business on April 14, 2021, the record date for the Annual
Meeting, there were 97,926,952 shares of Adverum common stock outstanding, each of which was entitled to one vote on each proposal at the Annual Meeting. Based on the
report from First Coast, a total of 76,091,742 shares of Common Stock, representing approximately 78% of the shares of Common Stock outstanding and entitled to vote, were present virtually Annual Meeting or represented by proxy, constituting a quorum to conduct business.
The voting results for each proposal, as provided by First Coast, are described below. For more information on each of these proposals, see the definitive
proxy statement filed by Adverum with the U.S. Securities and Exchange Commission on April 15, 2021.
Proposal 1. Election of Directors.
Adverum’s stockholders elected each of the Class I director nominees nominated by Adverum’s Board of Directors, each to hold office until the 2024 Annual
Meeting of Stockholders and until his or her successor is elected and has qualified, or until his or her earlier death, resignation or removal.
|
|
Votes
For
|
Votes
Withheld
|
|
|
Dawn Svoronos
|
48,299,685
|
5,236,404
|
|
|
Reed V. Tuckson, M.D.
|
53,131,087
|
405,002
|
|
|
Thomas Woiwode, Ph.D.
|
53,148,231
|
387,858
|
|
The votes for Sonic’s nominees, who were not elected the Class I directors, were as follows:
|
|
Votes
For
|
Votes
Withheld
|
|
|
Jean Bennett, M.D., Ph.D.
|
22,141,498
|
38,446
|
|
|
Jodi Cook, Ph.D.
|
22,132,266
|
47,678
|
|
|
Herbert Hughes
|
22,126,237
|
53,707
|
|
Proposal No. 2. Ratification of Selection of Independent Registered Public Accounting Firm.
Adverum’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year
ending December 31, 2021, by the following votes:
Votes For
|
Votes
Against
|
Abstentions
|
75,585,161
|
126,559
|
380,022
|
Proposal No. 3. Approval, on an Advisory Basis, of the Compensation of Adverum’s Named Executive Officers, as Disclosed in the Proxy
Statement.
Adverum’s stockholders approved, on an advisory basis, of the compensation of Adverum’s named executive officers, as disclosed in the proxy statement, by the
following votes:
Votes For
|
Votes
Against
|
Abstentions
|
46,353,570
|
29,287,503
|
74,960
|